





New Drug

Xanomeline/Trospium (Cobenfy)

Why it matters:

 Schizophrenia has long been treated with antipsychotics that block dopamine and serotonin receptors. Xanomeline/trospium is the first muscarinic agonist/antagonist combo approved for schizophrenia.

What else to know:

 Side effects of xanomeline/trospium were mostly GI-related (nausea, vomiting, constipation, etc) instead of the tardive dyskinesia and metabolic syndrome we normally see with older antipsychotics. Avoid use in patients with urinary retention and slowed gastric motility.

Manufacturer	Bristol Myers Squibb
FDA approved use	For treatment of schizophrenia in adult patients
FDA approval date	September 2024
Anticipated availability	Available now
Dosage and administration	<ul style="list-style-type: none">Starting dose: 50 mg/20 mg twice daily for at least 2 daysIncrease to 100 mg/20 mg twice daily for at least 5 daysMax dose: 125 mg/30 mg twice dailyTake on an empty stomach, 1 hour before or 2 hours after meals
Storage requirements	Store at controlled room temperature, 20°C to 25°C (68°F to 77°F)
Prescribing information	Xanomeline/Trospium Manufacturer



New Drug

Xanomeline/Trospium (Cobenfy)

References:

- Kaul I, Sawchak S, Correll CU, Kakar R, Breier A, Zhu H, Miller AC, Paul SM, Brannan SK. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. *Lancet*. 2024 Jan 13;403(10422):160-170.
- Kaul I, Sawchak S, Walling DP, Tamminga CA, Breier A, Zhu H, Miller AC, Paul SM, Brannan SK. Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial. *JAMA Psychiatry*. 2024 Aug 1;81(8):749-756.
- Product information for xanomeline/trospium (Cobenfy). Bristol Myers Squibb Company. Princeton, NJ 08543. September 2024.

Users of this resource are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication.

Copyright © 2024 by Therapeutic Research Center. All Rights Reserved. trchealthcare.com